Telomir Pharmaceuticals Sells $500K in Stock

Ticker: TELO · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1971532

Sentiment: neutral

Topics: unregistered-sale, equity-offering, capital-raise

TL;DR

Telomir just sold $500K in stock at $0.50/share, unregistered.

AI Summary

Telomir Pharmaceuticals, Inc. announced on December 9, 2024, that it entered into a securities purchase agreement for the sale of 1,000,000 shares of its common stock at a price of $0.50 per share, for a total of $500,000. This transaction is considered an unregistered sale of equity securities.

Why It Matters

The company is raising capital through an unregistered sale of equity, which could dilute existing shareholders and may indicate a need for immediate funding.

Risk Assessment

Risk Level: medium — The sale of unregistered securities can indicate potential financial distress or a need for quick capital, and it may lead to dilution for existing shareholders.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of the unregistered sale of equity securities?

The filing does not explicitly state the purpose of the unregistered sale of equity securities, but it is a common method for companies to raise capital.

Who purchased the 1,000,000 shares of common stock?

The filing does not disclose the identity of the purchasers of the 1,000,000 shares of common stock.

Are there any restrictions on the resale of these shares?

As these are unregistered securities, there are likely resale restrictions under Rule 144 or other exemptions, though the filing does not detail them.

What is the significance of the $0.50 per share price?

The $0.50 per share price represents the agreed-upon valuation for the sale of the company's common stock in this transaction.

Does this transaction require registration with the SEC?

No, this transaction is described as an 'Unregistered Sales of Equity Securities,' indicating it was conducted under an exemption from SEC registration requirements.

Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-12-11 16:01:10

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACUTICALS, INC. Dated: December 11, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing